Osteoprotegerin concentration and risk of cardiovascular outcomes in nine general population studies: Literature-based meta-analysis involving 26,442 participants
Recent experimental and epidemiological studies have suggested that osteoprotegerin, a key regulator in bone metabolism, may be involved in vascular calcification and atherosclerosis. Our aim was to reliably quantify the associations of osteoprotegerin concentration and incidence of first-ever cardi...
Saved in:
| Published in | PloS one Vol. 12; no. 8; p. e0183910 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
24.08.2017
Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1932-6203 1932-6203 |
| DOI | 10.1371/journal.pone.0183910 |
Cover
| Abstract | Recent experimental and epidemiological studies have suggested that osteoprotegerin, a key regulator in bone metabolism, may be involved in vascular calcification and atherosclerosis. Our aim was to reliably quantify the associations of osteoprotegerin concentration and incidence of first-ever cardiovascular disease outcomes in the general population.
Using the electronic databases MEDLINE, EMBASE and Web of Science (January 1975 and April 2017, no language restrictions), nine relevant studies were identified involving a total of 26,442 participants recruited from the general population. Over a mean follow-up of 8.5 years, 2,160 cardiovascular disease, 2,123 coronary heart disease, and 1,102 stroke outcomes were recorded. Study-specific risk ratios were combined with random-effects meta-analysis.
When comparing individuals in the top with those in the bottom third of osteoprotegerin concentration, the combined risk ratio was 1.83 (95% confidence interval: 1.46, 2.30; P<0.001; I2 = 76.8%) for cardiovascular disease, 1.72 for coronary heart disease (1.26, 2.37; P = 0.001; I2 = 83.5%), and 1.58 for stroke (1.18, 2.12; P = 0.002; I2 = 65.2%). Associations appeared stronger at younger age (P = 0.018 for cardiovascular disease), in studies that did not employ statistical adjustment (P = 0.023 for cardiovascular disease and 0.018 for coronary heart disease), and potentially in studies that measured osteoprotegerin in plasma rather than in serum (P = 0.005 for cardiovascular disease and 0.018 for coronary heart disease). Magnitudes of associations did not differ according to the proportion of males, geographical region, or osteoprotegerin assay manufacturer. There was no evidence for publication bias for any of the outcomes assessed (all P>0.05).
Elevated osteoprotegerin concentration is associated with an increased risk of incident cardiovascular disease in the general population. The mechanisms underlying this observation deserve further investigation. |
|---|---|
| AbstractList | Background
Recent experimental and epidemiological studies have suggested that osteoprotegerin, a key regulator in bone metabolism, may be involved in vascular calcification and atherosclerosis. Our aim was to reliably quantify the associations of osteoprotegerin concentration and incidence of first-ever cardiovascular disease outcomes in the general population.
Methods
Using the electronic databases MEDLINE, EMBASE and Web of Science (January 1975 and April 2017, no language restrictions), nine relevant studies were identified involving a total of 26,442 participants recruited from the general population. Over a mean follow-up of 8.5 years, 2,160 cardiovascular disease, 2,123 coronary heart disease, and 1,102 stroke outcomes were recorded. Study-specific risk ratios were combined with random-effects meta-analysis.
Results
When comparing individuals in the top with those in the bottom third of osteoprotegerin concentration, the combined risk ratio was 1.83 (95% confidence interval: 1.46, 2.30; P<0.001; I 2 = 76.8%) for cardiovascular disease, 1.72 for coronary heart disease (1.26, 2.37; P = 0.001; I 2 = 83.5%), and 1.58 for stroke (1.18, 2.12; P = 0.002; I 2 = 65.2%). Associations appeared stronger at younger age (P = 0.018 for cardiovascular disease), in studies that did not employ statistical adjustment (P = 0.023 for cardiovascular disease and 0.018 for coronary heart disease), and potentially in studies that measured osteoprotegerin in plasma rather than in serum (P = 0.005 for cardiovascular disease and 0.018 for coronary heart disease). Magnitudes of associations did not differ according to the proportion of males, geographical region, or osteoprotegerin assay manufacturer. There was no evidence for publication bias for any of the outcomes assessed (all P>0.05).
Conclusions
Elevated osteoprotegerin concentration is associated with an increased risk of incident cardiovascular disease in the general population. The mechanisms underlying this observation deserve further investigation. Recent experimental and epidemiological studies have suggested that osteoprotegerin, a key regulator in bone metabolism, may be involved in vascular calcification and atherosclerosis. Our aim was to reliably quantify the associations of osteoprotegerin concentration and incidence of first-ever cardiovascular disease outcomes in the general population. Using the electronic databases MEDLINE, EMBASE and Web of Science (January 1975 and April 2017, no language restrictions), nine relevant studies were identified involving a total of 26,442 participants recruited from the general population. Over a mean follow-up of 8.5 years, 2,160 cardiovascular disease, 2,123 coronary heart disease, and 1,102 stroke outcomes were recorded. Study-specific risk ratios were combined with random-effects meta-analysis. When comparing individuals in the top with those in the bottom third of osteoprotegerin concentration, the combined risk ratio was 1.83 (95% confidence interval: 1.46, 2.30; P0.05). Elevated osteoprotegerin concentration is associated with an increased risk of incident cardiovascular disease in the general population. The mechanisms underlying this observation deserve further investigation. Background Recent experimental and epidemiological studies have suggested that osteoprotegerin, a key regulator in bone metabolism, may be involved in vascular calcification and atherosclerosis. Our aim was to reliably quantify the associations of osteoprotegerin concentration and incidence of first-ever cardiovascular disease outcomes in the general population. Methods Using the electronic databases MEDLINE, EMBASE and Web of Science (January 1975 and April 2017, no language restrictions), nine relevant studies were identified involving a total of 26,442 participants recruited from the general population. Over a mean follow-up of 8.5 years, 2,160 cardiovascular disease, 2,123 coronary heart disease, and 1,102 stroke outcomes were recorded. Study-specific risk ratios were combined with random-effects meta-analysis. Results When comparing individuals in the top with those in the bottom third of osteoprotegerin concentration, the combined risk ratio was 1.83 (95% confidence interval: 1.46, 2.30; P<0.001; I2 = 76.8%) for cardiovascular disease, 1.72 for coronary heart disease (1.26, 2.37; P = 0.001; I2 = 83.5%), and 1.58 for stroke (1.18, 2.12; P = 0.002; I2 = 65.2%). Associations appeared stronger at younger age (P = 0.018 for cardiovascular disease), in studies that did not employ statistical adjustment (P = 0.023 for cardiovascular disease and 0.018 for coronary heart disease), and potentially in studies that measured osteoprotegerin in plasma rather than in serum (P = 0.005 for cardiovascular disease and 0.018 for coronary heart disease). Magnitudes of associations did not differ according to the proportion of males, geographical region, or osteoprotegerin assay manufacturer. There was no evidence for publication bias for any of the outcomes assessed (all P>0.05). Conclusions Elevated osteoprotegerin concentration is associated with an increased risk of incident cardiovascular disease in the general population. The mechanisms underlying this observation deserve further investigation. Background Recent experimental and epidemiological studies have suggested that osteoprotegerin, a key regulator in bone metabolism, may be involved in vascular calcification and atherosclerosis. Our aim was to reliably quantify the associations of osteoprotegerin concentration and incidence of first-ever cardiovascular disease outcomes in the general population. Methods Using the electronic databases MEDLINE, EMBASE and Web of Science (January 1975 and April 2017, no language restrictions), nine relevant studies were identified involving a total of 26,442 participants recruited from the general population. Over a mean follow-up of 8.5 years, 2,160 cardiovascular disease, 2,123 coronary heart disease, and 1,102 stroke outcomes were recorded. Study-specific risk ratios were combined with random-effects meta-analysis. Results When comparing individuals in the top with those in the bottom third of osteoprotegerin concentration, the combined risk ratio was 1.83 (95% confidence interval: 1.46, 2.30; P0.05). Conclusions Elevated osteoprotegerin concentration is associated with an increased risk of incident cardiovascular disease in the general population. The mechanisms underlying this observation deserve further investigation. Recent experimental and epidemiological studies have suggested that osteoprotegerin, a key regulator in bone metabolism, may be involved in vascular calcification and atherosclerosis. Our aim was to reliably quantify the associations of osteoprotegerin concentration and incidence of first-ever cardiovascular disease outcomes in the general population.Using the electronic databases MEDLINE, EMBASE and Web of Science (January 1975 and April 2017, no language restrictions), nine relevant studies were identified involving a total of 26,442 participants recruited from the general population. Over a mean follow-up of 8.5 years, 2,160 cardiovascular disease, 2,123 coronary heart disease, and 1,102 stroke outcomes were recorded. Study-specific risk ratios were combined with random-effects meta-analysis.When comparing individuals in the top with those in the bottom third of osteoprotegerin concentration, the combined risk ratio was 1.83 (95% confidence interval: 1.46, 2.30; P<0.001; I2 = 76.8%) for cardiovascular disease, 1.72 for coronary heart disease (1.26, 2.37; P = 0.001; I2 = 83.5%), and 1.58 for stroke (1.18, 2.12; P = 0.002; I2 = 65.2%). Associations appeared stronger at younger age (P = 0.018 for cardiovascular disease), in studies that did not employ statistical adjustment (P = 0.023 for cardiovascular disease and 0.018 for coronary heart disease), and potentially in studies that measured osteoprotegerin in plasma rather than in serum (P = 0.005 for cardiovascular disease and 0.018 for coronary heart disease). Magnitudes of associations did not differ according to the proportion of males, geographical region, or osteoprotegerin assay manufacturer. There was no evidence for publication bias for any of the outcomes assessed (all P>0.05).Elevated osteoprotegerin concentration is associated with an increased risk of incident cardiovascular disease in the general population. The mechanisms underlying this observation deserve further investigation. Recent experimental and epidemiological studies have suggested that osteoprotegerin, a key regulator in bone metabolism, may be involved in vascular calcification and atherosclerosis. Our aim was to reliably quantify the associations of osteoprotegerin concentration and incidence of first-ever cardiovascular disease outcomes in the general population. Using the electronic databases MEDLINE, EMBASE and Web of Science (January 1975 and April 2017, no language restrictions), nine relevant studies were identified involving a total of 26,442 participants recruited from the general population. Over a mean follow-up of 8.5 years, 2,160 cardiovascular disease, 2,123 coronary heart disease, and 1,102 stroke outcomes were recorded. Study-specific risk ratios were combined with random-effects meta-analysis. When comparing individuals in the top with those in the bottom third of osteoprotegerin concentration, the combined risk ratio was 1.83 (95% confidence interval: 1.46, 2.30; P<0.001; I2 = 76.8%) for cardiovascular disease, 1.72 for coronary heart disease (1.26, 2.37; P = 0.001; I2 = 83.5%), and 1.58 for stroke (1.18, 2.12; P = 0.002; I2 = 65.2%). Associations appeared stronger at younger age (P = 0.018 for cardiovascular disease), in studies that did not employ statistical adjustment (P = 0.023 for cardiovascular disease and 0.018 for coronary heart disease), and potentially in studies that measured osteoprotegerin in plasma rather than in serum (P = 0.005 for cardiovascular disease and 0.018 for coronary heart disease). Magnitudes of associations did not differ according to the proportion of males, geographical region, or osteoprotegerin assay manufacturer. There was no evidence for publication bias for any of the outcomes assessed (all P>0.05). Elevated osteoprotegerin concentration is associated with an increased risk of incident cardiovascular disease in the general population. The mechanisms underlying this observation deserve further investigation. Recent experimental and epidemiological studies have suggested that osteoprotegerin, a key regulator in bone metabolism, may be involved in vascular calcification and atherosclerosis. Our aim was to reliably quantify the associations of osteoprotegerin concentration and incidence of first-ever cardiovascular disease outcomes in the general population.BACKGROUNDRecent experimental and epidemiological studies have suggested that osteoprotegerin, a key regulator in bone metabolism, may be involved in vascular calcification and atherosclerosis. Our aim was to reliably quantify the associations of osteoprotegerin concentration and incidence of first-ever cardiovascular disease outcomes in the general population.Using the electronic databases MEDLINE, EMBASE and Web of Science (January 1975 and April 2017, no language restrictions), nine relevant studies were identified involving a total of 26,442 participants recruited from the general population. Over a mean follow-up of 8.5 years, 2,160 cardiovascular disease, 2,123 coronary heart disease, and 1,102 stroke outcomes were recorded. Study-specific risk ratios were combined with random-effects meta-analysis.METHODSUsing the electronic databases MEDLINE, EMBASE and Web of Science (January 1975 and April 2017, no language restrictions), nine relevant studies were identified involving a total of 26,442 participants recruited from the general population. Over a mean follow-up of 8.5 years, 2,160 cardiovascular disease, 2,123 coronary heart disease, and 1,102 stroke outcomes were recorded. Study-specific risk ratios were combined with random-effects meta-analysis.When comparing individuals in the top with those in the bottom third of osteoprotegerin concentration, the combined risk ratio was 1.83 (95% confidence interval: 1.46, 2.30; P<0.001; I2 = 76.8%) for cardiovascular disease, 1.72 for coronary heart disease (1.26, 2.37; P = 0.001; I2 = 83.5%), and 1.58 for stroke (1.18, 2.12; P = 0.002; I2 = 65.2%). Associations appeared stronger at younger age (P = 0.018 for cardiovascular disease), in studies that did not employ statistical adjustment (P = 0.023 for cardiovascular disease and 0.018 for coronary heart disease), and potentially in studies that measured osteoprotegerin in plasma rather than in serum (P = 0.005 for cardiovascular disease and 0.018 for coronary heart disease). Magnitudes of associations did not differ according to the proportion of males, geographical region, or osteoprotegerin assay manufacturer. There was no evidence for publication bias for any of the outcomes assessed (all P>0.05).RESULTSWhen comparing individuals in the top with those in the bottom third of osteoprotegerin concentration, the combined risk ratio was 1.83 (95% confidence interval: 1.46, 2.30; P<0.001; I2 = 76.8%) for cardiovascular disease, 1.72 for coronary heart disease (1.26, 2.37; P = 0.001; I2 = 83.5%), and 1.58 for stroke (1.18, 2.12; P = 0.002; I2 = 65.2%). Associations appeared stronger at younger age (P = 0.018 for cardiovascular disease), in studies that did not employ statistical adjustment (P = 0.023 for cardiovascular disease and 0.018 for coronary heart disease), and potentially in studies that measured osteoprotegerin in plasma rather than in serum (P = 0.005 for cardiovascular disease and 0.018 for coronary heart disease). Magnitudes of associations did not differ according to the proportion of males, geographical region, or osteoprotegerin assay manufacturer. There was no evidence for publication bias for any of the outcomes assessed (all P>0.05).Elevated osteoprotegerin concentration is associated with an increased risk of incident cardiovascular disease in the general population. The mechanisms underlying this observation deserve further investigation.CONCLUSIONSElevated osteoprotegerin concentration is associated with an increased risk of incident cardiovascular disease in the general population. The mechanisms underlying this observation deserve further investigation. |
| Audience | Academic |
| Author | Kiechl, Stefan Willeit, Peter Willeit, Johann Tschiderer, Lena Schett, Georg |
| AuthorAffiliation | 3 Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom Shanghai Institute of Hypertension, CHINA 2 Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany 1 Department of Neurology, Innsbruck Medical University, Innsbruck, Austria |
| AuthorAffiliation_xml | – name: 2 Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany – name: 1 Department of Neurology, Innsbruck Medical University, Innsbruck, Austria – name: 3 Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom – name: Shanghai Institute of Hypertension, CHINA |
| Author_xml | – sequence: 1 givenname: Lena surname: Tschiderer fullname: Tschiderer, Lena – sequence: 2 givenname: Johann surname: Willeit fullname: Willeit, Johann – sequence: 3 givenname: Georg surname: Schett fullname: Schett, Georg – sequence: 4 givenname: Stefan surname: Kiechl fullname: Kiechl, Stefan – sequence: 5 givenname: Peter orcidid: 0000-0002-1866-7159 surname: Willeit fullname: Willeit, Peter |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28837646$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk9tq3DAQhk1JaZq0b1BaQ6G00N1K1sF2Lgoh9BAIBHq6FWN57Cj1Sq4kL83r9EmrPSRkQyjFFzKj7_81-tEcZHvWWcyyZ5TMKSvpu0s3eQvDfEzlOaEVqyl5kD2mNStmsiBs79b_fnYQwiUhglVSPsr2i6pipeTycfbnPER0o3cRe_TG5tpZjTZ6iMbZHGybexN-5q7LNfjWuCUEPQ3gczdF7RYY8iSyxmLeo0UPQz66MQFreYhTazAc5Wcmpr04eZw1ELDNFxhhBqn_q2BWFks3LI3t80K-5bzIR_DRaDOCjeFJ9rCDIeDT7XqYff_44dvJ59nZ-afTk-OzmZakJLOiIxWAbjtJSbKomdQF48Cg67RoasBGEESuGdEEKMeGcS5qxnUpACtO2WH2YuM7Di6obbxBrUKkQlApEnG6IVoHl2r0ZgH-Sjkwal1wvlfrvgdUbcmEFB00nZYc27ZmREKtCwpVWXdNlbzeb0-bmgW2m8yHHdPdHWsuVO-WSoiS8KpOBq-3Bt79mjBEtTBB4zCARTdt-q54WbAV-vIOev_ttlQP6QLGdi6dq1em6lgQKqXgFUnU_B4qfS0uTHo82JlU3xG82REkJuLv2MMUgjr9-uX_2fMfu-yrW-wFwhAvghum1cMLu-Dz20nfRHw9BAngG0B7F4LH7gahRK1m7ToutZo1tZ21JDu6I9Mmrt99SsQM_xb_BacBMyc |
| CitedBy_id | crossref_primary_10_1038_s41598_021_82072_z crossref_primary_10_3892_etm_2024_12708 crossref_primary_10_1038_s41598_018_32738_y crossref_primary_10_15829_1560_4071_2021_4446 crossref_primary_10_3390_jcm13133778 crossref_primary_10_3390_jcm10132905 crossref_primary_10_2217_bmm_2022_0621 crossref_primary_10_1161_JAHA_123_032571 crossref_primary_10_1016_j_yjmcc_2019_08_011 crossref_primary_10_1111_tri_13847 crossref_primary_10_1161_JAHA_118_009012 crossref_primary_10_1007_s40618_018_0932_y crossref_primary_10_1038_s41574_018_0087_0 crossref_primary_10_47360_1995_4484_2021_411_417 crossref_primary_10_1007_s00726_019_02738_x crossref_primary_10_1093_labmed_lmz051 crossref_primary_10_1093_rheumatology_keac232 crossref_primary_10_1038_s41598_023_44554_0 crossref_primary_10_1186_s12933_018_0691_2 crossref_primary_10_1186_s12933_022_01605_6 crossref_primary_10_1038_s41598_021_94090_y crossref_primary_10_3390_jcm8070932 crossref_primary_10_1007_s11255_021_02988_3 crossref_primary_10_3390_cimb46090564 crossref_primary_10_1177_17455057231170059 crossref_primary_10_1186_s42358_024_00384_w crossref_primary_10_1093_eurheartj_ehz919 crossref_primary_10_1177_0003319718822625 crossref_primary_10_1002_hsr2_2253 crossref_primary_10_1161_JAHA_119_012729 crossref_primary_10_1038_s41413_023_00291_8 crossref_primary_10_1038_s41598_021_98177_4 crossref_primary_10_1097_TP_0000000000004903 crossref_primary_10_1007_s00467_021_04957_5 crossref_primary_10_1007_s12012_022_09741_x |
| Cites_doi | 10.1155/2016/1752854 10.1159/000358920 10.1371/journal.pone.0134266 10.12659/MSM.895434 10.1161/01.RES.0000149165.99974.12 10.1101/gad.12.9.1260 10.1016/j.atherosclerosis.2011.05.019 10.1177/1074248413511692 10.1155/2015/564934 10.1055/s-0034-1375611 10.1016/j.amjcard.2012.05.053 10.1161/01.ATV.0000204334.48195.6a 10.2217/bmm-2015-0029 10.1586/14779072.4.6.801 10.1001/jama.292.4.490 10.1001/jama.279.18.1477 10.1136/bmj.315.7109.629 10.1373/clinchem.2008.110593 10.1161/HYPERTENSIONAHA.107.087742 10.1016/j.clinbiochem.2014.05.006 10.2459/JCM.0000000000000229 10.1161/ATVBAHA.109.184101 10.1016/j.jacc.2010.03.013 10.1161/CIRCULATIONAHA.109.884866 10.1161/01.STR.0000129790.00318.a3 10.1136/bmj.327.7414.557 10.1530/EJE-10-0875 10.1373/clinchem.2003.023747 10.1007/s10654-016-0172-4 10.1136/heartjnl-2012-302240 10.1210/jc.2004-1895 10.1016/S0092-8674(00)80209-3 10.1111/j.1538-7836.2011.04222.x 10.1016/j.atherosclerosis.2008.03.026 10.1371/journal.pmed.1000097 10.1093/hmg/ddu386 10.1182/blood-2007-01-068395 10.1371/journal.pone.0147088 10.1161/ATVBAHA.109.199661 10.1111/jgh.13324 10.1161/JAHA.115.001833 10.1161/01.CIR.0000127957.43874.BB |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2017 Public Library of Science 2017 Tschiderer et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2017 Tschiderer et al 2017 Tschiderer et al |
| Copyright_xml | – notice: COPYRIGHT 2017 Public Library of Science – notice: 2017 Tschiderer et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2017 Tschiderer et al 2017 Tschiderer et al |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM DOA |
| DOI | 10.1371/journal.pone.0183910 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts ProQuest Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection Agricultural & Environmental Science Database ProQuest Central Essentials Biological Science Collection ProQuest Central Technology collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Materials Science Collection ProQuest Central Engineering Research Database Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Materials Science Database (NC LIVE) Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection Biological Sciences Agricultural Science Database ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection Proquest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Open Access Full Text |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Agricultural Science Database MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Open Access Full Text url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) |
| DocumentTitleAlternate | Osteoprotegerin and cardiovascular risk in the general population |
| EISSN | 1932-6203 |
| ExternalDocumentID | 1932155165 oai_doaj_org_article_d73565fabfc64edd9306a9c21a879fb8 PMC5570489 A501665480 28837646 10_1371_journal_pone_0183910 |
| Genre | Meta-Analysis Journal Article |
| GeographicLocations | Austria |
| GeographicLocations_xml | – name: Austria |
| GrantInformation_xml | – fundername: ; grantid: 843536 |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM 3V. BBORY CGR CUY CVF ECM EIF IPNFZ NPM RIG PMFND 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS RC3 7X8 ESTFP PUEGO 5PM AAPBV ABPTK BBAFP |
| ID | FETCH-LOGICAL-c6070-2f08aacdf610442936c234a3affc5b9aeb50ee4c30c0a14eb3445934c75ae8413 |
| IEDL.DBID | M48 |
| ISSN | 1932-6203 |
| IngestDate | Sun Oct 02 00:10:56 EDT 2022 Wed Aug 27 01:19:02 EDT 2025 Thu Aug 21 13:55:37 EDT 2025 Mon Sep 08 10:13:37 EDT 2025 Fri Jul 25 11:25:24 EDT 2025 Tue Jun 17 20:54:48 EDT 2025 Tue Jun 10 20:11:48 EDT 2025 Fri Jun 27 03:42:00 EDT 2025 Fri Jun 27 03:42:34 EDT 2025 Thu May 22 21:16:43 EDT 2025 Wed Feb 19 02:00:59 EST 2025 Thu Apr 24 23:11:49 EDT 2025 Tue Jul 01 02:09:37 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Language | English |
| License | This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c6070-2f08aacdf610442936c234a3affc5b9aeb50ee4c30c0a14eb3445934c75ae8413 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 Competing Interests: The authors have declared that no competing interests exist. |
| ORCID | 0000-0002-1866-7159 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1371/journal.pone.0183910 |
| PMID | 28837646 |
| PQID | 1932155165 |
| PQPubID | 1436336 |
| PageCount | e0183910 |
| ParticipantIDs | plos_journals_1932155165 doaj_primary_oai_doaj_org_article_d73565fabfc64edd9306a9c21a879fb8 pubmedcentral_primary_oai_pubmedcentral_nih_gov_5570489 proquest_miscellaneous_1932847239 proquest_journals_1932155165 gale_infotracmisc_A501665480 gale_infotracacademiconefile_A501665480 gale_incontextgauss_ISR_A501665480 gale_incontextgauss_IOV_A501665480 gale_healthsolutions_A501665480 pubmed_primary_28837646 crossref_primary_10_1371_journal_pone_0183910 crossref_citationtrail_10_1371_journal_pone_0183910 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20170824 |
| PublicationDateYYYYMMDD | 2017-08-24 |
| PublicationDate_xml | – month: 8 year: 2017 text: 20170824 day: 24 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2017 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | R Mogelvang (ref29) 2013; 99 D-H Song (ref38) 2016; 22 J Danesh (ref22) 1998; 279 W Lieb (ref28) 2010; 30 LC Hofbauer (ref6) 2004; 292 S Kiechl (ref26) 2004; 109 A Vik (ref33) 2011; 9 C Perez de Ciriza (ref4) 2015; 2015 A Callegari (ref16) 2014; 51 AG Semb (ref31) 2009; 29 JS Kwan (ref39) 2014; 23 G Zauli (ref13) 2007; 110 C Perez de Ciriza (ref40) 2014; 47 M-F Heymann (ref14) J Golledge (ref7) 2004; 35 M Nybo (ref41) 2008; 201 B Bumdelger (ref5) 2016; 11 N Bucay (ref9) 1998; 12 SM Venuraju (ref37) 2010; 55 O Aramburu-Bodas (ref47) 2015; 16 M Egger (ref24) 1997; 315 S Bernardi (ref19) 2016; 2016 E Di Angelantonio (ref44) 2009; 120 S Kiechl (ref34) 2004; 5 R Di Giuseppe (ref48) 2017; 32 JS Park (ref35) 2011; 164 WS Browner (ref25) 2001; 86 BA Mosheimer (ref12) 2005; 90 Gearry RB Voogd FA de (ref3) 2016; 31 S Koyama (ref10) 2014; 46 D Moher (ref21) 2009; 6 C Shen (ref32) 2012; 110 S Kiechl (ref2) 2006; 4 M Nybo (ref30) 2008; 54 WS Simonet (ref1) 1997; 89 ref20 B Toffoli (ref15) 2011; 218 H Uzui (ref36) 2014; 19 BYY Chan (ref43) 2003; 49 JR Lewis (ref27) 2015; 10 T Omland (ref49) 2007; 49 JPT Higgins (ref23) 2003; 327 A Vik (ref42) 2007; 98 P Collin-Osdoby (ref8) 2004; 95 WJ Sandberg (ref11) 2006; 26 RY Cao (ref18) 2016; 10 SE Hosbond (ref17) 2012; 46 P Willeit (ref45) 2015; 4 PC Haycock (ref46) 2014; 349 9600484 - JAMA. 1998 May 13;279(18):1477-82 26222774 - PLoS One. 2015 Jul 29;10(7):e0134266 27307249 - Eur J Epidemiol. 2017 Feb;32(2):113-123 24845712 - Clin Biochem. 2014 Sep;47(13-14):1279-85 9310563 - BMJ. 1997 Sep 13;315(7109):629-34 23135978 - Heart. 2013 Jan;99(2):106-10 24810471 - Horm Metab Res. 2014 Jul;46(8):581-6 15564564 - Circ Res. 2004 Nov 26;95(11):1046-57 21284802 - J Thromb Haemost. 2011 Apr;9(4):638-44 22762713 - Am J Cardiol. 2012 Oct 15;110(8):1138-42 19325145 - Arterioscler Thromb Vasc Biol. 2009 Jun;29(6):975-80 24642764 - J Vasc Res. 2014;51(2):118-31 15143295 - Stroke. 2004 Jul;35(7):1636-41 17598007 - Thromb Haemost. 2007 Jul;98(1):148-54 25469731 - J Cardiovasc Med (Hagerstown). 2015 Jun;16(6):438-43 15117849 - Circulation. 2004 May 11;109 (18):2175-80 19042987 - Clin Chem. 2008 Dec;54(12):1969-74 26078757 - Int J Endocrinol. 2015;2015:564934 9108485 - Cell. 1997 Apr 18;89(2):309-19 15728209 - J Clin Endocrinol Metab. 2005 May;90(5):2964-71 20447527 - J Am Coll Cardiol. 2010 May 11;55(19):2049-61 22506827 - Scand Cardiovasc J. 2012 Aug;46(4):203-11 26783750 - PLoS One. 2016 Jan 19;11(1):e0147088 9573043 - Genes Dev. 1998 May 1;12(9):1260-8 26896745 - J Gastroenterol Hepatol. 2016 Aug;31(8):1386-92 19917883 - Circulation. 2009 Dec 1;120(22):2177-87 15280347 - JAMA. 2004 Jul 28;292(4):490-5 19621072 - PLoS Med. 2009 Jul 21;6(7):e1000097 21679949 - Atherosclerosis. 2011 Sep;218(1):61-8 27200369 - Biomed Res Int. 2016;2016:1752854 17173497 - Expert Rev Cardiovasc Ther. 2006 Nov;4(6):801-11 26021436 - J Am Heart Assoc. 2015 May 28;4(6):e001833 20961967 - Eur J Endocrinol. 2011 Jan;164(1):69-74 17363729 - Blood. 2007 Jul 15;110(2):536-43 11158021 - J Clin Endocrinol Metab. 2001 Feb;86(2):631-7 24288395 - J Cardiovasc Pharmacol Ther. 2014 May;19(3):304-9 22402034 - Cytokine. 2012 May;58(2):300-6 20448212 - Arterioscler Thromb Vasc Biol. 2010 Sep;30(9):1849-54 14633883 - Clin Chem. 2003 Dec;49(12):2083-5 18490020 - Atherosclerosis. 2008 Nov;201(1):33-5 16424351 - Arterioscler Thromb Vasc Biol. 2006 Apr;26(4):857-63 27089223 - Biomark Med. 2016 May;10(5):525-35 25006006 - BMJ. 2014 Jul 08;349:g4227 27068490 - Med Sci Monit. 2016 Apr 12;22:1223-31 25080503 - Hum Mol Genet. 2014 Dec 15;23(24):6684-93 17470718 - Hypertension. 2007 Jun;49(6):1392-8 12958120 - BMJ. 2003 Sep 6;327(7414):557-60 |
| References_xml | – volume: 2016 start-page: 1752854 year: 2016 ident: ref19 article-title: ) Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease publication-title: BioMed research international doi: 10.1155/2016/1752854 – ident: ref14 article-title: Role of the OPG/RANK/RANKL triad in calcifications of the atheromatous plaques: Comparison between carotid and femoral beds publication-title: Cytokine – volume: 51 start-page: 118 issue: 2 year: 2014 ident: ref16 article-title: Increased Calcification in Osteoprotegerin-Deficient Smooth Muscle Cells: Dependence on Receptor Activator of NF-kappa B Ligand and Interleukin 6 publication-title: J. Vasc. Res doi: 10.1159/000358920 – ident: ref20 – volume: 10 start-page: e0134266 issue: 7 year: 2015 ident: ref27 article-title: Elevated Circulating Osteoprotegerin and Renal Dysfunction Predict 15-Year Cardiovascular and All-Cause Mortality: A Prospective Study of Elderly Women publication-title: PloS one doi: 10.1371/journal.pone.0134266 – volume: 22 start-page: 1223 year: 2016 ident: ref38 article-title: Relationships of OPG Genetic Polymorphisms with Susceptibility to Cardiovascular Disease: A Meta-Analysis publication-title: Medical science monitor: international medical journal of experimental and clinical research doi: 10.12659/MSM.895434 – volume: 95 start-page: 1046 issue: 11 year: 2004 ident: ref8 article-title: Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin publication-title: Circulation research doi: 10.1161/01.RES.0000149165.99974.12 – volume: 12 start-page: 1260 issue: 9 year: 1998 ident: ref9 article-title: osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification publication-title: Genes & development doi: 10.1101/gad.12.9.1260 – volume: 218 start-page: 61 issue: 1 year: 2011 ident: ref15 article-title: Osteoprotegerin promotes vascular fibrosis via a TGF-beta1 autocrine loop publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2011.05.019 – volume: 19 start-page: 304 issue: 3 year: 2014 ident: ref36 article-title: Effects of combination therapy with olmesartan and azelnidipine on serum osteoprotegerin in patients with hypertension publication-title: Journal of cardiovascular pharmacology and therapeutics doi: 10.1177/1074248413511692 – volume: 2015 start-page: 564934 year: 2015 ident: ref4 article-title: Osteoprotegerin in Cardiometabolic Disorders publication-title: International Journal of Endocrinology doi: 10.1155/2015/564934 – volume: 46 start-page: 581 issue: 8 year: 2014 ident: ref10 article-title: Osteoprotegerin is secreted into the coronary circulation: a possible association with the renin-angiotensin system and cardiac hypertrophy publication-title: Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme doi: 10.1055/s-0034-1375611 – volume: 110 start-page: 1138 issue: 8 year: 2012 ident: ref32 article-title: Relation between bone mineral density, bone loss and the risk of cardiovascular disease in a Chinese cohort publication-title: The American journal of cardiology doi: 10.1016/j.amjcard.2012.05.053 – volume: 5 start-page: 10 issue: 1 year: 2004 ident: ref34 article-title: Osteoprotegerin is a risk predictor of progressive atherosclerosis and cardiovascular disease publication-title: Atheroscler – volume: 46 start-page: 203 issue: 4 year: 2012 ident: ref17 article-title: Osteoprotegerin as a marker of atherosclerosis: a systematic update. Scandinavian cardiovascular journal publication-title: SCJ – volume: 26 start-page: 857 issue: 4 year: 2006 ident: ref11 article-title: Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization publication-title: Arteriosclerosis, thrombosis, and vascular biology doi: 10.1161/01.ATV.0000204334.48195.6a – volume: 10 start-page: 525 issue: 5 year: 2016 ident: ref18 article-title: Prognostic value of plasma biomarkers in patients with acute coronary syndrome: A review of advances in the past decade publication-title: Biomarkers in Medicine doi: 10.2217/bmm-2015-0029 – volume: 4 start-page: 801 issue: 6 year: 2006 ident: ref2 article-title: The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease publication-title: Expert review of cardiovascular therapy doi: 10.1586/14779072.4.6.801 – volume: 349 start-page: g4227 year: 2014 ident: ref46 article-title: Leucocyte telomere length and risk of cardiovascular disease: systematic review and meta-analysis publication-title: BMJ (Clinical research ed.) – volume: 292 start-page: 490 issue: 4 year: 2004 ident: ref6 article-title: Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases publication-title: JAMA doi: 10.1001/jama.292.4.490 – volume: 279 start-page: 1477 issue: 18 year: 1998 ident: ref22 article-title: Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies publication-title: JAMA doi: 10.1001/jama.279.18.1477 – volume: 315 start-page: 629 issue: 7109 year: 1997 ident: ref24 article-title: Bias in meta-analysis detected by a simple, graphical test publication-title: BMJ doi: 10.1136/bmj.315.7109.629 – volume: 54 start-page: 1969 issue: 12 year: 2008 ident: ref30 article-title: Lack of observed association between high plasma osteoprotegerin concentrations and ischemic stroke risk in a healthy population publication-title: Clinical chemistry doi: 10.1373/clinchem.2008.110593 – volume: 49 start-page: 1392 issue: 6 year: 2007 ident: ref49 article-title: Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function publication-title: Hypertension doi: 10.1161/HYPERTENSIONAHA.107.087742 – volume: 47 start-page: 1279 issue: 13–14 year: 2014 ident: ref40 article-title: Influence of pre-analytical and analytical factors on osteoprotegerin measurements publication-title: Clinical biochemistry doi: 10.1016/j.clinbiochem.2014.05.006 – volume: 16 start-page: 438 issue: 6 year: 2015 ident: ref47 article-title: Relationship between osteoprotegerin and mortality in decompensated heart failure with preserved ejection fraction publication-title: Journal of cardiovascular medicine doi: 10.2459/JCM.0000000000000229 – volume: 29 start-page: 975 issue: 6 year: 2009 ident: ref31 article-title: Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993–2003 publication-title: Arteriosclerosis, thrombosis, and vascular biology doi: 10.1161/ATVBAHA.109.184101 – volume: 55 start-page: 2049 issue: 19 year: 2010 ident: ref37 article-title: Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity publication-title: Journal of the American College of Cardiology doi: 10.1016/j.jacc.2010.03.013 – volume: 120 start-page: 2177 issue: 22 year: 2009 ident: ref44 article-title: B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.109.884866 – volume: 35 start-page: 1636 issue: 7 year: 2004 ident: ref7 article-title: Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis publication-title: Stroke doi: 10.1161/01.STR.0000129790.00318.a3 – volume: 98 start-page: 148 issue: 1 year: 2007 ident: ref42 article-title: Heparin induces mobilization of osteoprotegerin into the circulation publication-title: Thrombosis and haemostasis – volume: 327 start-page: 557 issue: 7414 year: 2003 ident: ref23 article-title: Measuring inconsistency in meta-analyses publication-title: BMJ doi: 10.1136/bmj.327.7414.557 – volume: 86 start-page: 631 issue: 2 year: 2001 ident: ref25 article-title: Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women publication-title: Journal of Clinical Endocrinology and Metabolism – volume: 164 start-page: 69 issue: 1 year: 2011 ident: ref35 article-title: Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus publication-title: European journal of endocrinology doi: 10.1530/EJE-10-0875 – volume: 49 start-page: 2083 issue: 12 year: 2003 ident: ref43 article-title: Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-kappa B ligand and osteoprotegerin in plasma and serum publication-title: Clinical chemistry doi: 10.1373/clinchem.2003.023747 – volume: 32 start-page: 113 issue: 2 year: 2017 ident: ref48 article-title: Plasma osteoprotegerin, its correlates, and risk of heart failure: a prospective cohort study publication-title: Eur. J. Epidemiol doi: 10.1007/s10654-016-0172-4 – volume: 99 start-page: 106 issue: 2 year: 2013 ident: ref29 article-title: Osteoprotegerin improves risk detection by traditional cardiovascular risk factors and hsCRP publication-title: Heart (British Cardiac Society) doi: 10.1136/heartjnl-2012-302240 – volume: 90 start-page: 2964 issue: 5 year: 2005 ident: ref12 article-title: Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes publication-title: J. Clin. Endocrinol. Metab doi: 10.1210/jc.2004-1895 – volume: 89 start-page: 309 issue: 2 year: 1997 ident: ref1 article-title: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density publication-title: Cell doi: 10.1016/S0092-8674(00)80209-3 – volume: 9 start-page: 638 issue: 4 year: 2011 ident: ref33 article-title: Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromso Study publication-title: Journal of thrombosis and haemostasis: JTH doi: 10.1111/j.1538-7836.2011.04222.x – volume: 201 start-page: 33 issue: 1 year: 2008 ident: ref41 article-title: Osteoprotegerin released from the vascular wall by heparin mainly derives from vascular smooth muscle cells publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2008.03.026 – volume: 6 start-page: e1000097 issue: 7 year: 2009 ident: ref21 article-title: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement publication-title: PLoS medicine doi: 10.1371/journal.pmed.1000097 – volume: 23 start-page: 6684 issue: 24 year: 2014 ident: ref39 article-title: Meta-analysis of genome-wide association studies identifies two loci associated with circulating osteoprotegerin levels publication-title: Human molecular genetics doi: 10.1093/hmg/ddu386 – volume: 110 start-page: 536 issue: 2 year: 2007 ident: ref13 article-title: Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo publication-title: Blood doi: 10.1182/blood-2007-01-068395 – volume: 11 start-page: e0147088 issue: 1 year: 2016 ident: ref5 article-title: Osteoprotegerin Prevents Development of Abdominal Aortic Aneurysms publication-title: PloS one doi: 10.1371/journal.pone.0147088 – volume: 30 start-page: 1849 issue: 9 year: 2010 ident: ref28 article-title: Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality publication-title: Arteriosclerosis, thrombosis, and vascular biology doi: 10.1161/ATVBAHA.109.199661 – volume: 31 start-page: 1386 issue: 8 year: 2016 ident: ref3 article-title: Osteoprotegerin: A novel biomarker for inflammatory bowel disease and gastrointestinal carcinoma publication-title: Journal of gastroenterology and hepatology doi: 10.1111/jgh.13324 – volume: 4 start-page: e001833 issue: 6 year: 2015 ident: ref45 article-title: Asymmetric dimethylarginine and cardiovascular risk: systematic review and meta-analysis of 22 prospective studies publication-title: Journal of the American Heart Association doi: 10.1161/JAHA.115.001833 – volume: 109 start-page: 2175 issue: 18 year: 2004 ident: ref26 article-title: Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease publication-title: Circulation doi: 10.1161/01.CIR.0000127957.43874.BB – reference: 14633883 - Clin Chem. 2003 Dec;49(12):2083-5 – reference: 27307249 - Eur J Epidemiol. 2017 Feb;32(2):113-123 – reference: 19042987 - Clin Chem. 2008 Dec;54(12):1969-74 – reference: 16424351 - Arterioscler Thromb Vasc Biol. 2006 Apr;26(4):857-63 – reference: 15117849 - Circulation. 2004 May 11;109 (18):2175-80 – reference: 15143295 - Stroke. 2004 Jul;35(7):1636-41 – reference: 24288395 - J Cardiovasc Pharmacol Ther. 2014 May;19(3):304-9 – reference: 9310563 - BMJ. 1997 Sep 13;315(7109):629-34 – reference: 26021436 - J Am Heart Assoc. 2015 May 28;4(6):e001833 – reference: 22402034 - Cytokine. 2012 May;58(2):300-6 – reference: 15564564 - Circ Res. 2004 Nov 26;95(11):1046-57 – reference: 9108485 - Cell. 1997 Apr 18;89(2):309-19 – reference: 20961967 - Eur J Endocrinol. 2011 Jan;164(1):69-74 – reference: 17363729 - Blood. 2007 Jul 15;110(2):536-43 – reference: 24845712 - Clin Biochem. 2014 Sep;47(13-14):1279-85 – reference: 27068490 - Med Sci Monit. 2016 Apr 12;22:1223-31 – reference: 18490020 - Atherosclerosis. 2008 Nov;201(1):33-5 – reference: 26078757 - Int J Endocrinol. 2015;2015:564934 – reference: 19325145 - Arterioscler Thromb Vasc Biol. 2009 Jun;29(6):975-80 – reference: 24642764 - J Vasc Res. 2014;51(2):118-31 – reference: 15728209 - J Clin Endocrinol Metab. 2005 May;90(5):2964-71 – reference: 20447527 - J Am Coll Cardiol. 2010 May 11;55(19):2049-61 – reference: 27200369 - Biomed Res Int. 2016;2016:1752854 – reference: 19621072 - PLoS Med. 2009 Jul 21;6(7):e1000097 – reference: 15280347 - JAMA. 2004 Jul 28;292(4):490-5 – reference: 22506827 - Scand Cardiovasc J. 2012 Aug;46(4):203-11 – reference: 12958120 - BMJ. 2003 Sep 6;327(7414):557-60 – reference: 27089223 - Biomark Med. 2016 May;10(5):525-35 – reference: 17470718 - Hypertension. 2007 Jun;49(6):1392-8 – reference: 26896745 - J Gastroenterol Hepatol. 2016 Aug;31(8):1386-92 – reference: 26222774 - PLoS One. 2015 Jul 29;10(7):e0134266 – reference: 23135978 - Heart. 2013 Jan;99(2):106-10 – reference: 25080503 - Hum Mol Genet. 2014 Dec 15;23(24):6684-93 – reference: 17173497 - Expert Rev Cardiovasc Ther. 2006 Nov;4(6):801-11 – reference: 21679949 - Atherosclerosis. 2011 Sep;218(1):61-8 – reference: 17598007 - Thromb Haemost. 2007 Jul;98(1):148-54 – reference: 19917883 - Circulation. 2009 Dec 1;120(22):2177-87 – reference: 9573043 - Genes Dev. 1998 May 1;12(9):1260-8 – reference: 25469731 - J Cardiovasc Med (Hagerstown). 2015 Jun;16(6):438-43 – reference: 20448212 - Arterioscler Thromb Vasc Biol. 2010 Sep;30(9):1849-54 – reference: 25006006 - BMJ. 2014 Jul 08;349:g4227 – reference: 11158021 - J Clin Endocrinol Metab. 2001 Feb;86(2):631-7 – reference: 22762713 - Am J Cardiol. 2012 Oct 15;110(8):1138-42 – reference: 24810471 - Horm Metab Res. 2014 Jul;46(8):581-6 – reference: 21284802 - J Thromb Haemost. 2011 Apr;9(4):638-44 – reference: 26783750 - PLoS One. 2016 Jan 19;11(1):e0147088 – reference: 9600484 - JAMA. 1998 May 13;279(18):1477-82 |
| SSID | ssj0053866 |
| Score | 2.428915 |
| SecondaryResourceType | review_article |
| Snippet | Recent experimental and epidemiological studies have suggested that osteoprotegerin, a key regulator in bone metabolism, may be involved in vascular... Background Recent experimental and epidemiological studies have suggested that osteoprotegerin, a key regulator in bone metabolism, may be involved in vascular... Background Recent experimental and epidemiological studies have suggested that osteoprotegerin, a key regulator in bone metabolism, may be involved in vascular... |
| SourceID | plos doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e0183910 |
| SubjectTerms | Arteriosclerosis Atherosclerosis Biocompatibility Biology and Life Sciences Bone turnover Calcification Calcification (ectopic) Cardiovascular disease Cardiovascular diseases Cardiovascular Diseases - blood Cardiovascular Diseases - epidemiology Confidence intervals Coronary artery disease Coronary heart disease Epidemiology Health risk assessment Health risks Heart Heart diseases Humans Incidence Males Medicine and Health Sciences Meta-analysis Metabolism Osteoprotegerin Osteoprotegerin - blood Patient outcomes Physical Sciences Physiological aspects Population (statistical) Population studies Population-based studies Research and Analysis Methods Risk Risk Factors Stroke Studies Tumor necrosis factor |
| SummonAdditionalLinks | – databaseName: DOAJ Open Access Full Text dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELXQnrggyldDCxiEBEikdeKJk3AriKogoBJQ1FvkOPaCVJIVyf4hfikzsTfaoErlwHU9trIz4_FzMvOGsadAfTZy4sNTqY7BFhBr0UAMWhd428iNGNu3ffykTs7g_Xl2vtXqi3LCPD2wV9xhk0vEHE7XziiwTVMixtWlSRNd5KWrxzJfUYrNZcrHYNzFSoVCOZknh8EuB6uutQeCQAFVzG4dRCNf_xSVF6uLrr8Mcv6dObl1FB3fZDcChuRH_tl32DXb3mI7YZf2_Hmgkn5xm_0-RSN2IxfDkur8uKEqxTZQ5XLdNpxyy3nnuJklpvJuPaAv4mo4qUUkypd-Ub6aOn7x3ucgvuIfJm7mmE7Fhv-0g4514DvBJTAG0osLnqqXAClf6ZDM3Q79HXZ2_Pbrm5M4dGWIjcL4EKdOFFqbxiHwwimlVCaVoKV2zmR1qW2dCWvBSGGETgAv6wBZKcHkmUZXSORdtmjRDruMpyUkRmRaNkpCg16TSVG73BUKTGosRExuTFSZQFlOnTMuqvE7XI5XF6_xigxbBcNGLJ5mrTxlxxXyr8n6kywRbo8_oBtWwQ2rq9wwYo_IdypfvTqFjeooQ0ytiFQvYk9GCSLdaCmrZ6nXfV-9O_32D0JfPs-EngUh16E6jA6VFPifiMxrJrk_k8TQYWbDu-TpG630FaH58dNphjM33n_58ONpmBalTL3Wdmsvg4gnlWXE7vnNMmmWOlvnClTE8tk2mql-PtL--D5ynhNTHBTl_f9hqz12PSVwJvCMgH22GH6t7QOElkP9cIwifwDZ93v1 priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELbK9sIFUV4NFDAICZBI68SOkyAh1KJWBcEWFYp6ixw_FqSShGb3D_FLmUmc0KAKuMZjK5mXx_HMN4Q8EdhnI0U8PBmrUNhMhIoZEQqlMjhtpJp17ds-zOXhiXh3mpyukflQC4NplYNP7By1qTX-I9_BQKO71UleNz9C7BqFt6tDCw3lWyuYVx3E2BWyDi45YTOyvrc__3g8-Gawbil9AR1Pox0vr-2mruw2w2ABK2kvbFAdjv_orWfNWd1eFor-mVF5YYs6uE6u-diS7vbKsEHWbHWDbHjrbekzDzH9_Cb5eQTCrTuMhgXW_1GN1YuVh9ClqjIUc85p7aieJKzSerUEfsFqMKmCCJUu-kVpM3YCo22fm_iSvh8xm0PcLQ39bpcqVB4HBZYA34g_NGgsXwgR00b5JO9q2d4iJwf7n98chr5bQ6gl-I0wdixTShsHARlMybnUMReKK-d0UubKlgmzVmjONFORgEO8EEnOhU4TBSoS8dtkVoEcNgmNcxFplihuJBcGtCnhrHSpy6TQsbYiIHwQUaE9lDl21Dgruvu5FI40PccLFGzhBRuQcJzV9FAe_6DfQ-mPtAjE3T2ozxeFt-vCpBxCYqdKp6WwxuRwBFO5jiOVpbkrs4A8RN0p-qrW0Z0UuwnE2hLB9gLyuKNAMI4Ks30WatW2xdujL_9B9Ol4QvTUE7ka2KGVr7CAb0KQrwnl1oQSXIqeDG-ipg9caYvfxgczB-2_fPjROIyLYgZfZetVTwORUMzzgNzpjWXkLHa8TqWQAUknZjRh_XSk-va1w0JHBDmR5Xf__lr3yNUYwzEGu4LYIrPl-creh2ByWT7wHuIXY115Ag priority: 102 providerName: ProQuest |
| Title | Osteoprotegerin concentration and risk of cardiovascular outcomes in nine general population studies: Literature-based meta-analysis involving 26,442 participants |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28837646 https://www.proquest.com/docview/1932155165 https://www.proquest.com/docview/1932847239 https://pubmed.ncbi.nlm.nih.gov/PMC5570489 https://doaj.org/article/d73565fabfc64edd9306a9c21a879fb8 http://dx.doi.org/10.1371/journal.pone.0183910 |
| Volume | 12 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELdG98ILYnwtMIpBSIBEKid27AQJoW1aGQg2NCjqW-Q4SUEqSWlaCf4d_lLuHDciqIi95CE-W8p9-Rzf_Y6QxwL7bCjEw5Oh9kURC1-zXPhC6xhOG8ow277t_Zk8nYi302i6QzY9Wx0Dm61HO-wnNVnORz--_3wFBv_Sdm1QwWbSaFFXxYjhlo81V7v2xgiT-UR3rwDWbW8vMWrxZci4K6b71yq9zcpi-neee7CY1822sPTv7Mo_tqvxdXLNxZn0sFWMPbJTVDfInrPkhj51cNPPbpJf5yDo2uI1zLAWkBqsZKwcnC7VVU4x_5zWJTW95FVar1egr7AaTKogWqWzdlG66LqC0abNU3xB33X4zT7unDn9Vqy0rx0mCiwBfhJ_btBQPhcipAvtEr6rVXOLTMYnn45Pfde5wTcSfIgflizW2uQlBGcwJeHShFxorsvSRFmiiyxiRSEMZ4bpQMCBXogo4cKoSIO6BPw2GVQgh31Cw0QEhkWa55KLHDQr4iwrVRlLYUJTCI_wjYhS42DNsbvGPLV3dQqONy3HUxRs6gTrEb-btWhhPf5Df4TS72gRlNu-qJez1Nl4misO4XGps9JIUeR5AscxnZgw0LFKyiz2yAPUnbStcO1cS3oYQdwtEXjPI48sBQJzVJj5M9PrpknfnH--BNHHix7RE0dU1sAOo121BXwTAn71KA96lOBeTG94HzV9w5UmRdux16sRzNxo__bhh90wLorZfFVRr1saiIpCnnjkTmssHWex-7WSQnpE9cyox_r-SPX1i8VFRzQ5ESd3L8Ofe-RqiAEag31CHJDBarku7kN4ucqG5IqaKnjGxwE-x6-HZPfo5OzDxdD-sBlaj_IbL_aBTA |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9QwDI_G7QFeEOPfCoMFBAIkurVNmrZIE9pg0x273dD-oL2VNE0PpNGW9U6Ir8MH4bNht2lZ0QS87PXiRFfbsZ3E_pmQJxz7bASIhyc8aXMdcls6Kbe5lCGcNgLl1O3b9iZieMzfnfgnC-RnWwuDaZWtTawNdVoovCNfx0CjftXxX5dfbewaha-rbQsNaVorpBs1xJgp7NjV37_BEa7aGL0FeT_1vJ3tozdD23QZsJUAfbe9zAmlVGkGgQQH68yE8hiXTGaZ8pNI6sR3tOaKOcqRLofDJ-d-xLgKfAmf5jJY9wpZ5HiBMiCLW9uT9wetLwBrIoQp2GOBu270Y60scr3mYHCClbvnHGLdN6DzDoPytKguCn3_zOA85xJ3bpDrJpalm43yLZEFnd8kS8ZaVPS5gbR-cYv82AdlKmpMiCnWG1KF1ZK5geylMk8p5rjTIqOqlyBLi_kM5AOrwaQcImI6bRalZdd5jFZNLuQrOu4wom30zin9omfSlgZ3BZYAW4wXKNQTL0EItJQmqTyfVbfJ8aXI7Q4Z5CCHZUK9iLvK8SVLBeMpaK_PnCQLslBw5SnNLcJaEcXKQKdjB4_TuH4PDOAI1XA8RsHGRrAWsbtZZQMd8g_6LZR-R4vA3_UPxdk0NnYkTgMGIXgmk0wJrtM0giOfjJTnyjCIsiS0yCrqTtxU0XbmK970IbYXCO5nkcc1BYJ_5JhdNJXzqopH-x_-g-jwoEf0zBBlBbBDSVPRAd-EoGI9ypUeJZgw1RteRk1vuVLFvzc7zGy1_-LhR90wLooZg7ku5g0NRF4eiyxyt9ksHWexw3YguLBI0NtGPdb3R_LPn2rsdUSs42F07-9_a5VcHR7tjePxaLJ7n1zzMBR0wCPxFTKYnc31AwhkZ8lDYy0o-XjZBuoX5QO1qw |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELdGJyFeEOPfCoMZBAIksqax4yRIE9rYqpWNbtoY2ltwHLsgjSQsrRBfh4_Dp-IuccKCJuBlr_XFanzn353ju98R8oRjn40A-fCEJx2uQ-5IN-UOlzKE00ag3Kp927uJ2Dnmb0_8kwXys6mFwbTKBhMroE5zhd_IBxhoVLc6_sDYtIiDrdHr4quDHaTwprVppyFtm4V0vaIbs0Ueu_r7NzjOlevjLdD9U88bbb9_s-PYjgOOEmD7jmfcUEqVGggqOCA1E8pjXDJpjPKTSOrEd7XmirnKlUMOB1HO_YhxFfgSXnPIYN4rZDEArw8HwcXN7cnBYeMXAFmEsMV7LBgOrK2sFXmm11wMVLCK95xzrHoItJ6iV5zm5UVh8J_ZnOfc4-gGuW7jWrpRG-ISWdDZTbJkkaOkzy299Ytb5Mc-GFZe8UNMsfaQKqyczCx9L5VZSjHfneaGqk6yLM3nM9AVzAYPZRAd02k9KS3aLmS0rPMiX9G9li_aQU-d0i96Jh1pOVhgCsBl_JhCPfESlEALaRPMs1l5mxxfit7ukF4Gelgm1Iv4ULm-ZKlgPAVL9pmbmMCEgitPad4nrFFRrCyNOnbzOI2ru8EAjlP1iseo2Ngqtk-c9qmiphH5h_wmar-VRRLw6of8bBpbTInTgEE4bmRilOA6TSM4_slIeUMZBpFJwj5ZRduJ64raFsriDR_ifIFEf33yuJJAIpAMt9RUzssyHu9_-A-ho8OO0DMrZHJYDiVtdQe8ExKMdSRXOpIAZ6ozvIyW3qxKGf_e-PBkY_0XDz9qh3FSzB7MdD6vZSAK81jUJ3frzdKuLHbbDgQXfRJ0tlFn6bsj2edPFQ87stfxMLr397-1Sq4CUMV748nufXLNw6jQBefEV0hvdjbXDyCmnSUPLVhQ8vGy8ekXiVy57w |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Osteoprotegerin+concentration+and+risk+of+cardiovascular+outcomes+in+nine+general+population+studies%3A+Literature-based+meta-analysis+involving+26%2C442+participants&rft.jtitle=PloS+one&rft.au=Tschiderer%2C+Lena&rft.au=Willeit%2C+Johann&rft.au=Schett%2C+Georg&rft.au=Kiechl%2C+Stefan&rft.date=2017-08-24&rft.pub=Public+Library+of+Science&rft.issn=1932-6203&rft.eissn=1932-6203&rft.volume=12&rft.issue=8&rft.spage=e0183910&rft_id=info:doi/10.1371%2Fjournal.pone.0183910&rft.externalDBID=ISR&rft.externalDocID=A501665480 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |